The concept of CC-93269 is in using an asymmetric 2-arm humanized IgG TCE that binds bivalently to BCMA and monovalently to CD3ε in a 2+1 format, so it would mediate interaction between T cells and BCMA-expressing myeloma cells to induce T cell receptor/CD3 crosslinking leading to T cell activation, and release of proinflammatory cytokines and cytolytic enzymes, resulting in myeloma cell death [219]. This evidence concerns the gene TNFRSF17 and plasma cell myeloma.